Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.44 |
| ▸ | HTR2B | P41595 | 10/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630299 | 1.00 | HTR2C (0.44) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| SCHEMBL5630306 | 1.00 | HTR2C (0.44) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL5631402 | 0.98 | HTR2C (0.44) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL5631397 | 0.98 | HTR2C (0.44) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL5633730 | 0.98 | HTR2C (0.44) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| SCHEMBL14442453 | 0.88 | HTR2C (0.46) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| SCHEMBL14442452 | 0.88 | HTR2C (0.46) | HTR2CHTR2BDPP4HTR2AHTR6 | |
| SCHEMBL19709598 | 0.86 | SLC6A2 (0.44) | HTR2CHTR2BHTR2A | |
| SCHEMBL31348108 | 0.86 | SLC6A2 (0.44) | HTR2CHTR2BHTR2A | |
| SCHEMBL5630822 | 0.85 | HTR2C (0.44) | HTR2CHTR2BDPP4HTR2ALATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885DPP4 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.